Findings

What do systematic reviews say?

1,337 questions · 1,354 findings · 566 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 307 · 22.7%GRADE not reported 81 · 6%Very low 424 · 31.3%Low 310 · 22.9%Moderate 189 · 14%High 43 · 3.2%

Hypnotics vs inactive control

Serious adverse events · adults with primary central sleep apnoea

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

Serious adverse events · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Parathyroidectomy vs observation

Serious adverse events · people with primary hyperparathyroidism

1 finding from 1 review

Parathyroidectomy for adults with primary hyperparathyroidism 2023 · Cochrane Headline outcomes only
3.35 [0.14, 78.6]
4 studies · 168 participants
Low

Summary of findings table ‐ Convalescent plasma vs standard plasma

Serious adverse events · individuals with moderate to severe disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes serious adverse events compared with standard plasma (very low certainty).

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.8 [0.55, 1.15]
3 studies · 327 participants
Very low

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Serious adverse events · outpatients withmild disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events compared with placebo or standard care alone (low certainty).

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.14 [0.66, 1.94]
1 study · 376 participants
Low

Corticosteroids vs placebo

Serious adverse events · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 118 participants
Very low

Corticosteroids vs modafinil

Serious adverse events · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Very low

Intervention not reported

Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fecal microbiota transplantation vs control

Serious adverse events · adults with recurrent Clostridioides difficile infection (rCDI)

Summary of findings table ‐ Fecal microbiota transplantation (FMT) showed no clear difference in serious adverse events compared with control (moderate certainty).

1 finding from 1 review

Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile) 2023 · Cochrane Headline outcomes only
RR 0.73 [0.38, 1.41]
6 studies · 320 participants
Moderate